Background Treatment-resistant depression (TRD) remains a major unmet need, as many patients relapse despite antidepressant therapy. Esketamine, a nasal spray formulation of the NMDA receptor antagonist, offers a new option for long-term maintenance after initial response. This pivotal Phase 3 trial evaluated its efficacy and safety in preventing r
1955 Reached2 Comments1 Likes
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
7718 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes